SCB
UTHR icon

Saudi Central Bank’s United Therapeutics UTHR Stock Holding History

Saudi Central Bank’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.5M Buy
2,761
+1,251
+83% +$705K 0.02% 392
2026
Q1 		$895K Buy
+1,510
New +$752K 0.02% 348
2025
Q2 		– Sell
-17
Closed -$5.24K – 518
2025
Q1 		$5.24K Buy
+17
New +$5.83K 0.03% 470

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Saudi Central Bank's UTHR Position: Q2 2026 in Review

Saudi Central Bank increased its United Therapeutics (UTHR) stake by 83% in Q2 2026, buying an estimated $705K and bringing the position to 2,761 shares worth $1.5M. The position accounts for 0.02% of the portfolio, ranked #392.

Saudi Central Bank first reported a position in UTHR in Q1 2025 and has held it in 3 quarters since. 882 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Saudi Central Bank held 2,761 shares of United Therapeutics worth $1.5M as of Q2 2026.
  • Saudi Central Bank bought 1,251 United Therapeutics shares in Q2 2026, an estimated $705K.
  • United Therapeutics made up 0.02% of Saudi Central Bank's portfolio in Q2 2026, its #392 holding.
  • Saudi Central Bank first reported a position in United Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • 882 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Saudi Central Bank's 13F filing for Q2 2026, filed 30 Jul 2026.